- /
- Supported exchanges
- / US
- / LLY.NYSE
Eli Lilly and Company (LLY NYSE) stock market data APIs
Eli Lilly and Company Financial Data Overview
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss; Olumiant; Omvoh; and Taltz. Further, it provides Emgality for migraine prevention and episodic cluster headache; and Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; BioArctic AB (publ) for new treatment; QurCan Therapeutics Inc for development of PLNP-enabled genetic medicine therapeutics for the treatment of central nervous system and peripheral nervous system; and Abbisko Therapeutics for discovery and development of medicines across multiple targets. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Eli Lilly and Company (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Eli Lilly and Company data using free add-ons & libraries
Get Eli Lilly and Company Fundamental Data
Eli Lilly and Company Fundamental data includes:
- Net Revenue: 79 666 M
- EBITDA: 41 707 M
- Earnings Per Share: 29
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-05
- EPS/Forecast: 6.01
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Eli Lilly and Company News
New
3 Great Biotech Stocks To Watch In October 2026
High energy costs are pushing inflation concerns back into focus after crude oil moved above US$100, and that kind of pressure often pushes investors toward higher risk, higher potential areas like bi...
Moderna Stock Slumps, but It’s Too Early to Panic
Moderna and Revolution Medicines have upcoming catalysts that could help sustain their gains, even as biotech stocks retreat. Continue Reading
Moderna and Novavax Stocks Slump as Biotech’s Rally Takes a Breather
Moderna and Revolution Medicines have upcoming catalysts that could help sustain their gains, even as biotech stocks retreat. Continue Reading
Eli Lilly’s Growth Is Exceptional. Is Its Valuation Asking Too Much?
Eli Lilly and Company (NYSE:LLY) has become one of the pharmaceutical industry's most important growth stories, but its valuation presents a harder question than whether demand for obesity treatments ...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.